Opko Health (OPK): Major Shareholder Dr. Frost has Already Bought Shares Worth Nearly $1.75 Million in 2025!

Opko Health Inc. (OPK) is a healthcare specialist that focuses on diagnostic tests through its subsidiary BioReference Laboratories, which serves approximately 11 million patients annually. In the pharmaceutical sector, the company markets RAYALDEE, a medication approved by the FDA for the treatment of secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease and vitamin D deficiency. For this year, the growth strategy is set to be expanded, among other things, through collaboration with Entera Bio to develop a once-daily...